Marwood Group Hires Nayan Ghosh to Head Life Sciences & HealthTech Practice
Marwood Group Hires Nayan Ghosh to Head Life Sciences & HealthTech Practice
Marwood Group, a leading, global healthcare advisory firm known for its deep expertise at the intersection of healthcare policy and commercial strategy, announced today the appointment of Nayan Ghosh as Director, Head of Life Sciences & HealthTech.
After first joining Marwood in 2017 to help expand the market access and commercial strategy capabilities of the Life Sciences & HealthTech practice, Ghosh took a hiatus in 2021 to serve as Head of Commercial & Regulatory Strategy at Arcade Therapeutics, targeting some of the first FDA authorizations for non-drug anxiety and depression treatments.
“Over the last decade, Marwood’s focus on Life Sciences & HealthTech has grown significantly, driven by its synergy with Marwood’s deep expertise, data and analytics capabilities related to healthcare services and delivery. Nayan played a large role in leading this growth, and we are excited to have him return,” said Marwood’s Senior Managing Director Lee Alvarez.
Marwood’s Life Sciences & HealthTech practice provides guidance related to market access, evidence, policy, and commercial strategy to investors, service providers, developers, and manufacturers of emerging innovations with the potential to transform the treatment, management, prevention, or diagnosis of disease.
“The mission of Marwood’s Life Sciences & HealthTech practice is to help life-changing healthcare innovations get into the hands of the patients and practitioners who need them,” said Ghosh. “However, healthcare systems are complex, and regulatory, reimbursement, and policy dynamics are slow to catch up to the dizzying pace of new breakthroughs, ranging from AI-based pathology to cell and gene therapy. I look forward to helping navigate these complexities so that those working on these innovations see success at every stage of their products’ lifecycles.”
About Marwood Group
As healthcare’s premier industry advisor, Marwood Group provides diligence and strategic consulting services to corporations and investors across provider, payor, HIT, outsourced services, and life sciences sectors. Marwood provides in-depth perspectives focused on policy, market strategy, reimbursement, compliance, big data analytics, and operations by leveraging its seasoned global team of healthcare professionals, proprietary data capabilities and extensive stakeholder reach. Marwood is headquartered in New York City with offices in Washington DC and London. To learn more, visit www.marwoodgroup.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508006905/en/
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now